Columns

Cloud-based drug design and development company, Cloud Pharmaceuticals, Inc., recently announced it has signed with THERAMetrics holding AG to collaborate on breakthrough treatments for orphan central nervous system (CNS) diseases and other indications. This strategic collaboration has as its primary points of interest Huntington’s disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy…

A team of scientists at the University of Louisville are determined to find out if a promising treatment, VX15, an investigational monoclonal antibody, can delay the onset of or slow disease progression of Huntington’s Disease (HD). The study titled SIGNAL is a Phase II clinical trial that aims to determine the…

In a new study entitled “Spatial mapping of juxtacrine axo-glial interactions identifies novel molecules in peripheral myelination” a team of scientists reports a new method for capturing and understanding the molecular mechanisms behind brain cellular interactions, a key event for a healthy and fully functional brain which may…

In a new study entitled “Delayed identification and diagnosis of Huntington’s disease due to psychiatric symptoms” researchers present a case study of a female patient with 58 years old diagnosed with Huntington’s disease as a consequence of psychiatric symptoms prior to motor symptoms. The study was published in the International…

Tapping into the cerebrospinal fluid (CSF) of patients with Huntington’s disease may give insights on disease onset, diminished functional ability and potential therapeutic agents for treatment. A recent study investigated whether huntingtin (HTT) protein could be detected in CSF, and the research team behind the investigation created an assay with…

The New York Blood Center (NYBC), one of the largest independent, community-based blood centers in the country, serving the more than 20 million people who live in the New York metropolitan area, recently announced it has partnered with the University of California Davis Health System to develop specialized lines of stem…

Researchers at the University of Pittsburgh and the Carnegie Mellon University recently reported the first non-invasive brain-imaging tool to visualize the brain’s basal ganglia regions, which are thought to be defective in some neurological disorders including Huntington’s disease. The study entitled “In vivo characterization of…

A groundbreaking research initiative on cell reprogramming for drug development against Huntington’s disease recently received $1.19 million worth of funding for the next 3 years, thanks to the Health Research Council to University of Auckland. Lead investigator and neuroscientist, Associate Professor Bronwen Connor, will attempt to better understand the disease, particularly…

The Huntington’s Disease Society of America has selected Dr. Neil Aronin, a professor of medicine, to be this year’s recipient of its prestigious Research Award in recognition of his transformative contributions to what is now known about Huntington’s disease, a rare, inherited neurodegenerative condition. Dr. Aronin is currently the chief of…

Courtagen Life Sciences, Inc., released several new Next Generation Sequencing tests designed to evaluate people with epilepsy and mitochondrial disease. Mitochondrial diseases are inherited or chronic illness. They can occur either at birth or may develop later, and include problems with development and cognition. They may cause poor growth, lack of coordination, weakness, pain and seizures.